If you would like to be considered for one of the clinical trials listed below please contact:
Kristy Averette, MSN, RN, CCRP
Research Practice Manager
kristy.averette@duke.edu
Phone: 919-681-5797
Gorlin Syndrome
- Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome.
- Status: Enrolling participants.
- PI: Dr. Meenal Kheterpal
- More Details
Advanced Skin Cancers
- A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients with Advanced Cutaneous Malignancies.
- Status: Enrolling participants.
- PI: Dr. Meenal Kheterpal
- More Details
Hidradenitis Suppurativa (HS)
- Role of hormones in hidradenitis suppurativa and other skin diseases.
- Status: Enrolling participants
- PI: Dr. Tarannum Jaleel
- More Details
- Biorepository of Patients with Hidradenitis Suppurativa (HS): Determination of potential predictors and moderators of treatment response in patients with HS.
- Status: Enrolling participants
- PI: Dr. Tarannum Jaleel
- More Details
- A Study to Test the Long-term Treatment of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa (BE HEARD EXT).
- Status: Open, not enrolling at this time
- PI: Dr. Tarannum Jaleel
- More Details
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS).
- Status: Enrolling participants
- PI: Dr. Tarannum Jaleel
- More Details
- A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa.
- Status: Enrolling participants
- PI: Dr. Tarannum Jaleel
- More Details
Psoriasis
- A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1)
- Status: Enrolling participants
- PI: Dr. John Murray
- More Details
Lupus
- A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST).
- Status: Enrolling participants
- PI: Dr. Anne Marano
- More Details
Prurigo Nodularis
- A Prospective Observational Study of Patients Receiving Dupilumab for Prurigo Nodularis
- Status: Enrolling participants
- PI: Dr. Amber Fresco